# Acepodia Announces First Patient Dosed in Phase 1 Trial of ACE723, a Novel Dual-Payload Antibody-Drug Conjugate

- Source: PR Newswire M&A
- Published: 2026-11-05T07:14:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/acepodia-announces-first-patient-dosed-in-phase-1-trial-of-ace723-a-novel-dual-payload-antibody-drug-conjugate-302930382.html
- Canonical: https://groundlevelnews.com/story/acepodia-announces-first-patient-dosed-in-phase-1-trial-of-ace723-a-no-8c1ec6/

ACE723 is the first candidate from Acepodia's AD2C platform to enter human testing ALAMEDA, Calif., and TAIPEI, Nov. 5, 2026 /PRNewswire/ -- Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell therapies and antibody-drug conjugates, today announced...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._